Kymera Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $18.67
- Today's High:
- $19.17
- Open Price:
- $18.89
- 52W Low:
- $18.415
- 52W High:
- $39.85
- Prev. Close:
- $19.08
- Volume:
- 289521
Company Statistics
- Market Cap.:
- $1.10 billion
- Book Value:
- 7.928
- Revenue TTM:
- $51.67 million
- Operating Margin TTM:
- -333.32%
- Gross Profit TTM:
- $-117422000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -19.48%
- Return on Equity TTM:
- -37.82%
Company Profile
Kymera Therapeutics Inc had its IPO on 2020-08-21 under the ticker symbol KYMR.
The company operates in the Healthcare sector and Biotechnology industry. Kymera Therapeutics Inc has a staff strength of 181 employees.
Stock update
Shares of Kymera Therapeutics Inc opened at $18.89 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $18.67 - $19.17, and closed at $18.99.
This is a -0.47% slip from the previous day's closing price.
A total volume of 289,521 shares were traded at the close of the day’s session.
In the last one week, shares of Kymera Therapeutics Inc have slipped by -4.38%.
Kymera Therapeutics Inc's Key Ratios
Kymera Therapeutics Inc has a market cap of $1.10 billion, indicating a price to book ratio of 3.1685 and a price to sales ratio of 33.3041.
In the last 12-months Kymera Therapeutics Inc’s revenue was $51.67 million with a gross profit of $-117422000 and an EBITDA of $-170056992. The EBITDA ratio measures Kymera Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Kymera Therapeutics Inc’s operating margin was -333.32% while its return on assets stood at -19.48% with a return of equity of -37.82%.
In Q2, Kymera Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 43.4%.
Kymera Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.79 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Kymera Therapeutics Inc’s profitability.
Kymera Therapeutics Inc stock is trading at a EV to sales ratio of 25.2366 and a EV to EBITDA ratio of -7.6904. Its price to sales ratio in the trailing 12-months stood at 33.3041.
Kymera Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $581.95 million
- Total Liabilities
- $54.60 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $10.77 million
- Dividend Payout Ratio
- 0%
Kymera Therapeutics Inc ended 2024 with $581.95 million in total assets and $0 in total liabilities. Its intangible assets were valued at $581.95 million while shareholder equity stood at $435.43 million.
Kymera Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $54.60 million in other current liabilities, 6000.00 in common stock, $-463517000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $52.39 million and cash and short-term investments were $367.57 million. The company’s total short-term debt was $3,797,000 while long-term debt stood at $0.
Kymera Therapeutics Inc’s total current assets stands at $385.40 million while long-term investments were $104.76 million and short-term investments were $315.19 million. Its net receivables were $4.12 million compared to accounts payable of $3.75 million and inventory worth $0.
In 2024, Kymera Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $10.77 million.
Comparatively, Kymera Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $18.99
- 52-Week High
- $39.85
- 52-Week Low
- $18.415
- Analyst Target Price
- $54.88
Kymera Therapeutics Inc stock is currently trading at $18.99 per share. It touched a 52-week high of $39.85 and a 52-week low of $39.85. Analysts tracking the stock have a 12-month average target price of $54.88.
Its 50-day moving average was $20.9 and 200-day moving average was $27.66 The short ratio stood at 21.16 indicating a short percent outstanding of 0%.
Around 142.7% of the company’s stock are held by insiders while 10596.8% are held by institutions.
Frequently Asked Questions About Kymera Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.